)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
LENZ Therapeutics
LENZ Therapeutics (LENZ) investor relations material
LENZ Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Q3 VIZZ product sales reached $2.6M, up 50% QoQ, with more than 38,000 paid prescriptions and momentum continuing into Q4.
The October reorganization redirects resources toward consumer marketing, access and sales growth, targeting a >50% reduction in 2027 operating expenses.
CEO Eef Schimmelpennink transitions effective Dec. 1, 2026; CFO Dan Chevallard becomes interim CEO while the board searches for a permanent successor.
Financial highlights
Q3 revenue was $3.4M: $2.6M in product sales and $0.8M in license revenue; Q3 2025 revenue was $12.5M, all license revenue.
Nine-month 2026 revenue was $10.8M, including $6.0M in product sales and $4.8M in license revenue, versus $17.5M in nine-month 2025, all license revenue.
Q3 net loss was $31.0M, or $0.99 per share; nine-month net loss was $104.4M, or $3.33 per share.
Cash, cash equivalents and marketable securities totaled $197.3M at Sept. 30, 2026; management expects resources to fund operations for at least 12 months from issuance.
Outlook and guidance
2027 operating expenses target $70M–$75M, excluding stock-based compensation, representing a reduction of >50% from prior estimates.
More than 70% of projected 2027 operating spend is allocated to consumer-driven sales and marketing; the planned organization is ~40 FTEs.
Reorganization activities are expected to be substantially complete in Q4 2026, with estimated net restructuring charges of $5M.
Commercial priorities include broad ECP engagement, consumer demand generation and access through retail, ePharmacy and telehealth.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from LENZ Therapeutics
- VIZZ pairs sustained near-vision benefits with early prescription traction and global expansion.LENZ
Corporate presentation - Q2 2026 revenue grew to $5.5M on VIZZ sales and licensing, with net loss at $31.9M.LENZQ2 2026
- New presbyopia eye drop delivers rapid, lasting vision improvement and targets broad U.S. adoption.LENZMorgan Stanley 23rd Annual Global Healthcare Conference
- Presbyopia eye drop launch sees strong adoption, positive feedback, and robust market potential.LENZTD Cowen 46th Annual Health Care Conference
- Q1 2026 revenue hit $1.9M, with strong VIZZ uptake, global expansion, and a $41.5M net loss.LENZQ1 2026
- Board recommends electing three directors and ratifying Ernst & Young LLP as auditor for 2026.LENZProxy filing
- Virtual meeting to elect three directors and ratify Ernst & Young LLP as auditor.LENZProxy filing
- VIZZ launch drove $1.6M in Q4 sales, strong adoption, and major launch investments.LENZQ4 2025
- LNZ100 advances toward FDA approval with strong clinical data and $226.2M pro forma cash.LENZQ2 2024
Next LENZ Therapeutics earnings date
Q4 202617 Mar, 2027
LENZ Therapeutics
Next LENZ Therapeutics earnings date
Q4 202617 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
LENZ Therapeutics Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative ophthalmic therapies aimed at improving vision. The company's primary focus is on treating presbyopia, a common age-related condition that affects near vision. LENZ Therapeutics is currently advancing its lead product candidates, LNZ100 and LNZ101, which are in Phase III clinical trials. These products are aceclidine-based eye drops designed to restore near vision for individuals with presbyopia. The company is headquartered in Del Mar, California, and its shares are listed on the NASDAQ.